Breast cancer · 30 regimens
Cost vs Efficacy · 10 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Pembrolizumab monotherapy Variant #01 | TNBC | R 286 955 | 14d | ~5.8 mo | ~15.5 mo | ~13 | ~R 3 730 419 PFS proxy · indirect | 40 |
Bevacizumab monotherapy Variant #08 | — | R 57 246 | 21d | ~4.3 mo | ~23.7 mo | ~7 | ~R 400 725 PFS proxy · indirect | 1 |
Dose-dense Cyclophosphamide and Doxorubicin (ddAC) N/A - secondary systemic drug | — | R 6 111 | 14d | — | — | — | — | 1 |
Carboplatin and Paclitaxel (CP) Variant #38 | TNBC | R 5 031 | 21d | ~12.6 mo | ~28.2 mo | ~19 | ~R 95 583 PFS proxy · indirect | 2 |
MMM Variant #01 | — | R 4 514 | 21d | — | — | — | — | — |
Doxorubicin and Paclitaxel (AT) Variant #08 | — | R 3 176 | 21d | — | ~25.3 mo | — | — | 1 |
Epirubicin and Paclitaxel (EP) Variant #01 | — | R 3 172 | 21d | ~10.8 mo | ~22.4 mo | ~16 | ~R 50 755 PFS proxy · indirect | 2 |
TAC (Docetaxel) Variant #01 | — | R 2 667 | 21d | — | — | — | — | 2 |
Epirubicin monotherapy Variant #01 | — | R 2 611 | 21d | — | — | — | — | 1 |
FEC Variant #01 | — | R 2 364 | 21d | — | — | — | — | 7 |
Paclitaxel monotherapy Variant #46 | ERBB2 | R 2 220 | 28d | ~6.4 mo | ~16.8 mo | ~7 | ~R 15 537 PFS proxy · indirect | 28 |
Paclitaxel monotherapy Variant #46 | — | R 2 220 | 28d | ~6.4 mo | ~16.8 mo | ~7 | ~R 15 537 PFS proxy · indirect | 28 |
Capecitabine monotherapy Variant #17 | TNBC | R 2 219 | 21d | — | — | — | — | 2 |
Capecitabine monotherapy Variant #17 | — | R 2 219 | 21d | — | — | — | — | 2 |
Cyclophosphamide and Docetaxel (TC) Variant #01 | — | R 2 212 | 21d | — | — | — | — | — |
Cyclophosphamide and Epirubicin (EC) Variant #01 | — | R 1 775 | 21d | ~8.0 mo | ~20.3 mo | ~12 | ~R 21 298 PFS proxy · indirect | 1 |
Doxorubicin monotherapy Variant #10 | — | R 1 293 | 21d | ~6.8 mo | ~13.8 mo | ~10 | ~R 12 932 PFS proxy · indirect | 3 |
FAC Variant #01 | TNBC | R 1 045 | 28d | — | — | — | — | 1 |
FAC Variant #01 | — | R 1 045 | 28d | — | — | — | — | 1 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | — | R 718 | 21d | — | — | — | — | 1 |
Cyclophosphamide and Doxorubicin (AC) Variant #01 | TNBC | R 718 | 21d | — | — | — | — | 1 |
CMFT Variant #01 | — | R 585 | 28d | — | — | — | — | — |
Vinorelbine monotherapy Variant #01 | — | R 583 | 21d | ~4.0 mo | ~10.1 mo | ~6 | ~R 3 500 PFS proxy · indirect | 18 |
CMF Variant #01 | TNBC | R 515 | 28d | — | — | — | — | 4 |
CMF Variant #01 | — | R 515 | 28d | — | — | — | — | 4 |
Docetaxel monotherapy N/A - secondary systemic drug | — | R 243 | 28d | ~8.0 mo | ~11.5 mo | ~9 | ~R 2 188 PFS proxy · indirect | 11 |
Dose-dense Epirubicin monotherapy Partial | — | — | — | — | — | — | — | — |
Dose-dense Doxorubicin monotherapy Partial | — | — | — | — | — | — | — | — |
Dose-dense Cyclophosphamide monotherapy Partial | — | — | — | — | — | — | — | — |
Bevacizumab-containing therapy Partial | TNBC | — | — | — | — | — | — | — |
30 of 30 regimens shown